@LennMcD @ACRheumDC Do policies affect medication access, costs, reimbursements, telehealth, or your life as a rheumatology provider or patients? Contact - quick and easy! https://t.co/TvMlXiIZQR @RheumNow #ACR24 https://t.co/plnUtl7Kml https://t.co/lFGx7hzlKy

• Contact Federal Policymakers
• https://x.com/ericdeinmd/status/1858156009358831975/photo/1
• https://twitter.com/ericdeinmd/status/1857850440357953789

#Blinded by results? 😊 #Ocular #involvement in #GPA 👇 Helped by #rituximab 👁️ #GPA Difficult Proptosis Pseudotumour Conjunctivitis Scleritis Vasculitis Ocular muscles - diplopia Small case series ‘author defined’ remission in 80% 👍 #RTX #abst0726 @rheumnow #ACR24 https://t.co/GHptelOTyv

• https://x.com/Janetbirdope/status/1858148771579777129/photo/1

If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/EVLUyvpBfD

• https://x.com/Janetbirdope/status/1858148798331031999/photo/1
• https://x.com/Janetbirdope/status/1858148798331031999/photo/1

Improved fertility in women with RA when treated with a Treat-to-Target (T2T) approach aimed at remission. Key findings: - Shorter time to pregnancy (TTP) in PreCARA cohort (84 days) vs. PARA cohort (196 days). - Increased TNF-inhibitor use and lower NSAID/prednisone use in the… https://t.co/YyD2lpXVRC https://t.co/LH5LMOH8al

• https://x.com/i/web/status/1858149341715698133
• https://x.com/synovialjoints/status/1858149341715698133/photo/1

@ACRheumDC Check out the ACR policy position statements Created by volunteer-led, non-partisan group of GAC committee - changes based on the needs of the ACR members @cdowneymd https://t.co/oAFfYUct4y @RheumNow #ACR24 https://t.co/MmVd8XYs0j

• ACR Policy and Position Statements
• https://x.com/ericdeinmd/status/1858150005602730063/photo/1

Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis Interesting as lots Of data On #enthesitis wIL23i Likely all Effective #PsA Rx helps #tenosynovitis some have ➡️ data on #efficacy ⬆️ bio rationale #ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj

• https://twitter.com/janetbirdope/status/1857188344100221389

If you are not at the table, you are on the menu https://t.co/c4anIn3aue @cdowneymd @ACRheumDC Join a committee RheumPAC Write a letter Write a post card at ACR Hub at #ACR24 Advocacy office hours with ACR staff #Act4Arthritis & Advocacy 101 on Cap Hill @RheumNow https://t.co/bpilydxEpB

• About ACR Advocacy
• https://x.com/ericdeinmd/status/1858151693004795960/photo/1
• https://x.com/ericdeinmd/status/1858151693004795960/photo/1

The post hoc analysis of the SURPASS study evaluated predictors of radiographic spinal progression in axial spondyloarthritis patients treated with IL-17A (secukinumab) or TNF inhibitors over 2 years. Key findings: - New syndesmophytes: 18.2% (SEC 150 mg), 15.8% (SEC 300 mg),… https://t.co/jke6OHdPjZ

• https://x.com/i/web/status/1858151857870315827

The future use of a panel of immunological urinary biomarkers as a liquid biopsy for the management of lupus nephritis. Plenary Abstr#1642 @RheumNow #ACR24 https://t.co/waSRVd7FV7

• https://x.com/synovialjoints/status/1858151875658359020/photo/1

@LennMcD @ACRheumDC Current congress (118th) - very tight margins, paralyzed by the ‘24 elections. Now in lame duck Many ACR policies made into bills - PA, step rx, copay accumulator, workforce, loan repayment, incr Rx transparency Needs to be passed into law @RheumNow #ACR24 https://t.co/1elEUiUAmh

• https://x.com/ericdeinmd/status/1858153751158132967/photo/1

@DrLauraCoates presented Sex differences in clinical presentations of PsA: -Women present >polyarthritis, enthesitis and worse PROs which translates to ⬆️ DAPSAs in spite of less Rx progression. -Men more oligoarthritis, axial involvement, higher skin disease. #ACR24… https://t.co/iapZF0nZWX https://t.co/jZ79WfxZwh

• https://x.com/i/web/status/1858154076623487286
• https://x.com/AdelaCastro222/status/1858154076623487286/photo/1
• https://x.com/AdelaCastro222/status/1858154076623487286/photo/1
• https://x.com/AdelaCastro222/status/1858154076623487286/photo/1

🔥Sex matters in PsA 🔑Differences in : ➡️clinical phenotypes ➡️radiographic progression ➡️disease impact ➡️pt perception of disease ➡️response to Rx #ACR24 @RheumNow https://t.co/iOXQmoxgp0

• https://x.com/CaoilfhionnMD/status/1858154269611856207/photo/1

Dr @andreafava presents their noninvasive biomarker panel that predicted the probability of histologically active LN. Panel outperformed UPCR, C3, C4 & antidsDNA. Aid in clinical-decision making? Lots of potential for monitoring tx response. @Rheumnow #ACR24 abs1642 #ACRbest https://t.co/C7ZNdvbIQ7

• https://x.com/RHEUMarampa/status/1858154864032829497/photo/1
• https://x.com/RHEUMarampa/status/1858154864032829497/photo/1

@LennMcD @ACRheumDC Many ACR priorities in bills, needs to be passed in law Victories: Incr NIH biomedical research funding, added to DoD funds Medicare reimbursem and telehealth needs addressed by lame duck congress Get involved, reach out, write letters @RheumNow #ACR24 https://t.co/7oCvUFWpx4

• https://x.com/ericdeinmd/status/1858154977287381390/photo/1
• https://x.com/ericdeinmd/status/1858154977287381390/photo/1
• https://x.com/ericdeinmd/status/1858154977287381390/photo/1

Impressive Plenary @andreafava just finished Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options Improving at 3 mos predicts response at 1 year Could reduce biopsies / modulate tx! #ACR24 @RheumNow Abstr#1642 #ACRbest https://t.co/Gi6u6hAGzj

• https://x.com/EBRheum/status/1858155100948124140/photo/1
• https://x.com/EBRheum/status/1858155100948124140/photo/1